Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 16;2010(6):CD006517.
doi: 10.1002/14651858.CD006517.pub3.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy

Eliza H Humphreys  1 , Larry W Chang, Jamal Harris
Affiliations

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy

Eliza H Humphreys et al. Cochrane Database Syst Rev. .

Abstract

Background: Highly active antiretroviral therapy has reduced the morbidity and mortality of patients with HIV/AIDS. A common first-line ART regimen in low-resource settings includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs). If treatment failure occurs, a change to second-line therapy is necessary.

Objectives: This systematic review aimed to assess the optimum antiretroviral regimen for patients with HIV who fail first-line therapy (ART-naive) with a recommended World Health Organization (WHO) first-line regimen.

Search strategy: Electronic databases and conference proceedings were searched with relevant search terms without limits to language.

Selection criteria: Randomised controlled trials of HIV-infected adolescent and adult patients administered second-line ART after virologic failure of a first-line regimen were included. Observational studies were included given the insufficient number of trials identified. The primary outcome measure included mortality. Secondary outcome measures included rate of adverse events, change in mean CD4 cell count, clinical resolution of symptoms, proportion of patients achieving undetectable viral load (VL) and acquisition of genotypic mutations.

Data collection and analysis: Two authors assessed each reference for inclusion and exclusion criteria established a priori. Data were abstracted independently using a standardised abstraction form. Risk of bias was assessed for individual studies and the GRADE approach for assessing the quality of evidence across a body of evidence was also applied.

Main results: One randomised trial in 136 patients studied maintaining lamivudine in second-line regimens or not. There was no difference in virological outcomes in the group who maintained lamivudine and those who did not in their subsequent regimens. Two other small observational studies reported in abstract form also did not report a difference in the proportion of those with viral suppression after six months and time to HIV-1 RNA suppression among those on a lamivudine (3TC) or emtricitabine (FTC) regimen compared to those on a 3TC/FTC-sparing second-line regimen. There were no trials identified comparing boosted protease inhibitors (PIs) or nucleoside backbone combinations after first-line failure on non-thymidine analog combinations. Observational studies of populations starting ART in resource-limited settings suggest that short-term response on boosted PI-based regimens is encouraging.

Authors' conclusions: There is limited evidence to evaluate second-line therapies in patients with HIV who fail first-line treatment with a WHO-recommended regimen. One randomised trial in 136 patients and two observational studies (both of low quality) suggest no difference in virological suppression whether or not lamivudine is maintained in a second-line regimen. While outcomes of second-line regimens with boosted PIs are favourable in general, there are no studies comparing boosted PIs directly in populations starting second-line regimens. Current recommendations are based on available resources and patient- and public-health-level considerations.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Flow Chart Search Results
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
3
3
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
4
4
Forest plot of comparison: 1 Maintaining lamivudine or not, outcome: 1.5 Proportion achieving viral suppression.
5
5
Forest plot of comparison: 1 Maintaining lamivudine or not, outcome: 1.6 immunologic outcome.
1.5
1.5. Analysis
Comparison 1 Maintaining lamivudine or not, Outcome 5 Proportion achieving viral suppression.
1.6
1.6. Analysis
Comparison 1 Maintaining lamivudine or not, Outcome 6 immunologic outcome.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Fox 2006 {published data only}
    1. Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine‐containing regimen: the COLATE trial. Antiviral therapy 2006;11(6):761‐70. [PUBMED: 17310820] - PubMed
Hull 2009 {published data only}
    1. Hull M, Moore D, et al. A lamivudine (3TC)‐based backbone in conjunction with a boosted protease inhibitor (PI) is sufficient to achieve virologic suppression in the presence of M184V mutations. Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12‐15, 2009, San Francisco, CA. Abstract H‐916.
Murphy 2008 {published data only}
    1. Murphy RA, Sunpath H, et al. [Lopinavir/ritonavir (LPV/r) + 2 nucleoside analogues as second‐line ART in Protease‐inhibitor naive adults in South Africa: Outcomes and Adverse Effects]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 3‐6, 2008. Poster Abstract No. 831.
Pujades‐Rodriguez 2008 {published data only}
    1. Pujades‐Rodriguez M, O'Brien D, Humblet P, Calmy A. Second‐line antiretroviral therapy in resource‐limited settings: the experience of Medecins Sans Frontieres. AIDS (London, England) 2008;22(11):1305‐12. [PUBMED: 18580610] - PubMed

References to studies excluded from this review

de Mendoza 2006 {published data only}
    1. Mendoza C, Valer L, Ribera E, Barreiro P, Martin‐Carbonero L, Ramirez G, et al. Performance of six different ritonavir‐boosted protease inhibitor‐based regimens in heavily antiretroviral‐experienced HIV‐infected patients. HIV clinical trials 2006;7(4):163‐71. [PUBMED: 17065028] - PubMed
Dragsted 2003 {published data only}
    1. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1‐infected patients: the MaxCmin1 Trial. The Journal of infectious diseases 2003;188(5):635‐42. [PUBMED: 12934178] - PubMed
Dragsted 2005 {published data only}
    1. Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV‐1‐infected patients: the MaxCmin2 trial. Antiviral therapy 2005;10(6):735‐43. [PUBMED: 16218173] - PubMed
Gomo 2008 {published data only}
    1. Gomo Z, Walker S, Hakim J, et al. Impact of lopinavir/ritonavir (Kaltera) based second‐line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting. XVII International AIDS Conference; August 3‐8, 2008. Mexico City, Mexico.
Hosseinipour 2009 {published data only}
    1. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Clinical, Immunological, and Virological Outcomes of Second‐line Treatment, Malawi. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, CA, February 8‐11, 2009:Paper # 605.
Sproat 2005 {published data only}
    1. Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, et al. The influence of the M184V mutation in HIV‐1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antiviral therapy 2005;10(2):357‐61. [PUBMED: 15865231] - PubMed

References to ongoing studies

ANRS12169 {published data only}
    1. Multicentric, Non‐Inferiority, Randomized, Non‐Blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV‐1‐Infected Patients With Treatment Failure After 1st Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal).
EARNEST {published data only}
    1. A Randomised Controlled Trial to Evaluate Options for Second‐line Therapy in Patients Failing a First‐line 2NRTI + NNRTI Regimen in Africa.
HIV NAT {published data only}
    1. The HIV Second‐Line Therapy Antiretroviral Study in Patients Who Failed NNRTI‐Based Regimens.
NCT00931463 {published data only}
    1. A Randomised Open‐Label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2‐3 N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First‐Line NNRTI+2N(t)RTI Therapy.
SARA (ISRTCN53817258) {published data only}
    1. Second‐line Anti‐Retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir‐boosted lopinavir (Aluvia® tablets) following initiation with 24 weeks of combination therapy in second‐line anti‐retroviral therapy in Africa.

Additional references

Bendavid 2009
    1. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding Antiretroviral Options in Resource‐Limited Settings‐A Cost‐Effectiveness Analysis. Journal of acquired immune deficiency syndromes (1999) 2009. [PUBMED: 19448557] - PMC - PubMed
Bierman 2009
    1. Bierman WF, Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir‐boosted protease inhibitors: a systematic review. AIDS (London, England) 2009; Vol. 23, issue 3:279‐91. [PUBMED: 19114854] - PubMed
Boyd 2007
    1. Boyd MA, Cooper DA. Second‐line combination antiretroviral therapy in resource‐limited settings: facing the challenges through clinical research. AIDS (London, England) 2007;21 Suppl 4:S55‐63. [PUBMED: 17620754] - PubMed
Campbell 2005
    1. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, et al. Antiviral activity of lamivudine in salvage therapy for multidrug‐resistant HIV‐1 infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(2):236‐42. [PUBMED: 15983922] - PubMed
Castagna 2006
    1. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV‐1‐infected patients harbouring a lamivudine‐resistant virus: a randomized pilot study (E‐184V study). AIDS (London, England) 2006;20(6):795‐803. [PUBMED: 16549962] - PubMed
Devereux 2001
    1. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations. Journal of medical virology 2001;65(2):218‐24. [PUBMED: 11536226] - PubMed
Egger 2009
    1. Egger M, Keiser O. Switching to second‐line antiretroviral therapy in resource‐limited settings: comparison of programmes with and without viral load monitoring. AIDS (London, England) 2009. [PUBMED: 19531928] - PMC - PubMed
Eron 2006
    1. Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir‐ritonavir versus lopinavir‐ritonavir, each in combination with abacavir‐lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non‐inferiority trial. Lancet 2006;368(9534):476‐82. [PUBMED: 16890834] - PubMed
Gallant 2007
    1. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource‐limited countries. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007; Vol. 44, issue 3:453‐5. [PUBMED: 17205458] - PubMed
Gilks 2006
    1. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public‐health approach to antiretroviral treatment against HIV in resource‐limited settings. Lancet 2006;368(9534):505‐10. [PUBMED: 16890837] - PubMed
GRADEpro 2008 [Computer program]
    1. Jan Brozek, Andrew Oxman, Holger Schunemann. Version 3.2 for Windows.. GRADE Working Group, 2008.
Gupta 2009
    1. Gupta RK, Hill A, Sawyer AW, Cozzi‐Lepri A, Wyl V, Yerly S, et al. Virological monitoring and resistance to first‐line highly active antiretroviral therapy in adults infected with HIV‐1 treated under WHO guidelines: a systematic review and meta‐analysis. The Lancet infectious diseases 2009;9(7):409‐17. [PUBMED: 19555900] - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 2008;336(7650):924‐6 [PubMed: 18436948]. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions.. Chichester: John Wiley & Sons Ltd, 2008.
Holtgrave 2005
    1. Holtgrave DR. Causes of the decline in AIDS deaths, United States, 1995‐2002: prevention, treatment or both?. International journal of STD & AIDS 2005;16(12):777‐81. [PUBMED: 16336756] - PubMed
Hozo 2005
    1. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005;5(1):13. [PUBMED: 15840177] - PMC - PubMed
Humphreys 2007
    1. Humphreys EH, Hernandez LB, Rutherford GW. Antiretroviral regimens for patients with HIV who fail first‐line antiretroviral therapy. Cochrane database of systematic reviews (Online) 2007, (4):CD006517. [PUBMED: 17943914] - PubMed
Keiser 2009
    1. Keiser O, Tweya H, Braitstein P, Dabis F, Macphail P, Boulle A, et al. Mortality after failure of antiretroviral therapy in sub‐Saharan Africa. Tropical medicine & international health : TM & IH 2009. [PUBMED: 20003034] - PMC - PubMed
Llibre 2009
    1. Llibre JM. First‐line boosted protease inhibitor‐based regimens in treatment‐naive HIV‐1‐infected patients‐‐making a good thing better. AIDS reviews 2009;11(4):215‐22. [PUBMED: 19940948] - PubMed
Mills 2009
    1. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once‐daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment‐naive, HIV‐1‐infected patients: 96‐week analysis. AIDS (London, England) 2009;23(13):1679‐88. [PUBMED: 19487905] - PubMed
Molina 2008
    1. Molina JM, Andrade‐Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once‐daily atazanavir/ritonavir versus twice‐daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral‐naive HIV‐1‐infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372(9639):646‐55. [PUBMED: 18722869] - PubMed
Ortiz 2008
    1. Ortiz R, Dejesus E, Khanlou H, Voronin E, Lunzen J, Andrade‐Villanueva J, et al. Efficacy and safety of once‐daily darunavir/ritonavir versus lopinavir/ritonavir in treatment‐naive HIV‐1‐infected patients at week 48. AIDS (London, England) 2008;22(12):1389‐97. [PUBMED: 18614861] - PubMed
Palella 1998
    1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine 1998;338(13):853‐60. [PUBMED: 9516219] - PubMed
Paredes 2009
    1. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, et al. In vivo fitness cost of the M184V mutation in multidrug‐resistant human immunodeficiency virus type 1 in the absence of lamivudine. Journal of virology 2009;83(4):2038‐43. [PUBMED: 19019971] - PMC - PubMed
Renaud‐Thery 2007
    1. Renaud‐Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, et al. Use of antiretroviral therapy in resource‐limited countries in 2006: distribution and uptake of first‐ and second‐line regimens. AIDS (London, England) 2007;21 Suppl 4:S89‐95. [PUBMED: 17620758] - PubMed
Sungkanuparph 2007
    1. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second‐line antiretroviral regimen for HIV type 1‐infected patients whose initial regimen of a fixed‐dose combination of stavudine, lamivudine, and nevirapine fails. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(3):447‐52. [PUBMED: 17205457] - PubMed
Trottier 2009
    1. Trottier B, Thomas R, Nguyen V‐K, et al. Should inactive nucleoside/tide reverse transcriptase inhibitors (NRTIs) still be used in salvage regimens, with new classes/generations of antiretrovirals in three‐class‐experienced, multi‐drug resistant patients?. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19‐22, 2009:Abtract No. TUPDB205.
UNAIDS 2009
    1. UNAIDS2009 Report on global AIDS epidemic. Available online at: http://data.unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf. Accessed December 15, 2009.
Wainberg 1996
    1. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, et al. Enhanced fidelity of 3TC‐selected mutant HIV‐1 reverse transcriptase. Science (New York, N.Y.) 1996;271(5253):1282‐5. [PUBMED: 8638110] - PubMed
Wells 2009
    1. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. [The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm Accessed 22 June 2009.
WHO 2006
    1. Guidelines for Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach. Geneva: World Health Organization, 2006. - PubMed
WHO 2009
    1. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009. Available at: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf.

Publication types